5-FU is the main chemotherapeutic agent currently used for the treatment of advanced GC [135], however, recent studies have found that 5-FU promotes a rise in Exo-PD-L1 via the miR-940/Cbl-b/STAT5A network, leading to immunosuppression in patients with late-stage disease [121]. Here, CD274 is linked to gastric cancer.